US6143746A
(en)
|
1994-01-21 |
2000-11-07 |
Icos Corporation |
Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
|
GB9423910D0
(en)
|
1994-11-26 |
1995-01-11 |
Pfizer Ltd |
Therapeutic agents
|
US5958926A
(en)
*
|
1996-11-01 |
1999-09-28 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
|
US6331543B1
(en)
|
1996-11-01 |
2001-12-18 |
Nitromed, Inc. |
Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
|
DE19881732D2
(de)
|
1997-11-12 |
2000-08-24 |
Bayer Ag |
2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
|
WO1999043674A1
(fr)
*
|
1998-02-27 |
1999-09-02 |
Kyowa Hakko Kogyo Co., Ltd. |
Remedes contre les dysfonctionnements de l'erection
|
WO1999059584A1
(en)
*
|
1998-05-20 |
1999-11-25 |
Schering Corporation |
Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
|
EP0967284A1
(en)
*
|
1998-05-28 |
1999-12-29 |
Pfizer Limited |
Phosphodiesterases
|
US6331571B1
(en)
|
1998-08-24 |
2001-12-18 |
Sepracor, Inc. |
Methods of treating and preventing attention deficit disorders
|
US6974838B2
(en)
|
1998-08-24 |
2005-12-13 |
Sepracor Inc. |
Methods of treating or preventing pain using sibutramine metabolites
|
US6339106B1
(en)
|
1999-08-11 |
2002-01-15 |
Sepracor, Inc. |
Methods and compositions for the treatment and prevention of sexual dysfunction
|
US6476078B2
(en)
|
1999-08-11 |
2002-11-05 |
Sepracor, Inc. |
Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
|
US6326379B1
(en)
|
1998-09-16 |
2001-12-04 |
Bristol-Myers Squibb Co. |
Fused pyridine inhibitors of cGMP phosphodiesterase
|
JP2000178204A
(ja)
*
|
1998-10-05 |
2000-06-27 |
Eisai Co Ltd |
ホスフォジエステラ―ゼ阻害剤を含有する口腔内速崩壊性錠剤
|
US6743443B1
(en)
|
1998-10-05 |
2004-06-01 |
Eisai Co., Ltd. |
Tablets immediately disintegrating in the oral cavity
|
JP2000191518A
(ja)
*
|
1998-10-19 |
2000-07-11 |
Eisai Co Ltd |
溶解性の改善された口腔内速崩壊性錠剤
|
UA67802C2
(uk)
|
1998-10-23 |
2004-07-15 |
Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. |
Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
|
AU3724400A
(en)
*
|
1999-03-08 |
2000-09-28 |
Merck & Co., Inc. |
Methods and compositions for treating erectile dysfunction
|
WO2000066114A1
(en)
*
|
1999-04-30 |
2000-11-09 |
Lilly Icos Llc |
Treatment of female arousal disorder
|
ES2187234A1
(es)
*
|
1999-04-30 |
2003-05-16 |
Lilly Icos Llc |
Forma de dosificacion oral para tratar la disfuncion sexual.
|
US6451807B1
(en)
*
|
1999-04-30 |
2002-09-17 |
Lilly Icos, Llc. |
Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
|
US6943166B1
(en)
*
|
1999-04-30 |
2005-09-13 |
Lilly Icos Llc. |
Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
|
SK287869B6
(sk)
*
|
1999-08-03 |
2012-02-03 |
Icos Corporation |
Beta-carboline pharmaceutical compositions
|
US6399826B1
(en)
|
1999-08-11 |
2002-06-04 |
Sepracor Inc. |
Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
|
GB9922124D0
(en)
*
|
1999-09-17 |
1999-11-17 |
Pfizer Ltd |
Phosphodiesterase enzymes
|
US6436944B1
(en)
*
|
1999-09-30 |
2002-08-20 |
Pfizer Inc. |
Combination effective for the treatment of impotence
|
SK4562002A3
(en)
|
1999-10-11 |
2003-04-01 |
Pfizer |
5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)- dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors
|
UA74826C2
(en)
*
|
2000-05-17 |
2006-02-15 |
Ortho Mcneil Pharm Inc |
?-carboline derivatives as phosphodiesterase inhibitors
|
UA72611C2
(uk)
*
|
2000-05-17 |
2005-03-15 |
Орто-Макнейл Фармацевтикал, Інк. |
Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
|
MXPA02012076A
(es)
*
|
2000-06-07 |
2003-06-06 |
Lilly Icos Llc |
Compuestos quimicos.
|
US20030153575A1
(en)
*
|
2000-06-08 |
2003-08-14 |
Orme Mark W. |
Tetracyclic diketopiperazine compounds as pdev inhibitors
|
CA2412594C
(en)
*
|
2000-06-23 |
2009-03-17 |
Lilly Icos Llc |
Pyrazino[1',2':1,6]pyrido[3-4-5] indole derivatives
|
CA2413510C
(en)
*
|
2000-06-26 |
2007-12-11 |
Lilly Icos Llc |
Condensed pyrazindione derivatives
|
CA2423357C
(en)
*
|
2000-08-02 |
2008-05-27 |
Lilly Icos Llc |
Fused heterocyclic derivatives as phosphodiesterase inhibitors
|
WO2002020058A1
(fr)
*
|
2000-09-06 |
2002-03-14 |
Tanabe Seiyaku Co., Ltd. |
Preparations administrees par voie orale
|
US6821978B2
(en)
*
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
ES2244659T3
(es)
*
|
2000-10-02 |
2005-12-16 |
Lilly Icos Llc |
Derivados de hexahidropirazino (1'2':1,6)-pirido(3,4-b)indol-1,4-diona para el tratamiento de trastornos cardiovasculares y disfuncion erectil.
|
WO2002038563A2
(en)
*
|
2000-11-08 |
2002-05-16 |
Lilly Icos Llc |
Condensed pyrazindione derivatives as pde inhibitors
|
CN100372536C
(zh)
*
|
2001-02-15 |
2008-03-05 |
田边三菱制药株式会社 |
在口腔中迅速崩解的片剂
|
DE10118305A1
(de)
*
|
2001-04-12 |
2002-10-17 |
Bayer Ag |
Zusammensetzungen zur nasalen Applikation
|
US6610887B2
(en)
|
2001-04-13 |
2003-08-26 |
Sepracor Inc. |
Methods of preparing didesmethylsibutramine and other sibutramine derivatives
|
MXPA03011082A
(es)
*
|
2001-06-05 |
2004-07-08 |
Lilly Icos Llc |
Derivados de pirazino-1',2': 1,6-prirido-3,4-b-indol-1,4-diona.
|
CN1781920A
(zh)
*
|
2001-08-28 |
2006-06-07 |
先灵公司 |
多环鸟嘌呤磷酸二酯酶v抑制剂
|
US20030087963A1
(en)
|
2001-09-13 |
2003-05-08 |
Senanayake Chris H. |
Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
|
MXPA04004370A
(es)
*
|
2001-11-09 |
2004-08-11 |
Schering Corp |
Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
|
CN1280292C
(zh)
|
2001-11-14 |
2006-10-18 |
奥索-麦克尼尔药品公司 |
用作磷酸二酯酶抑制剂的被取代的四环吡咯并喹诺酮衍生物
|
US7335680B2
(en)
*
|
2001-12-20 |
2008-02-26 |
Laboratoires Serono Sa |
Pyrrolidine derivatives as prostaglandin modulators
|
US7276529B2
(en)
|
2002-03-20 |
2007-10-02 |
Celgene Corporation |
Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
US7893101B2
(en)
|
2002-03-20 |
2011-02-22 |
Celgene Corporation |
Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
|
US6962940B2
(en)
|
2002-03-20 |
2005-11-08 |
Celgene Corporation |
(+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
|
US7208516B2
(en)
|
2002-03-20 |
2007-04-24 |
Celgene Corporation |
Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
|
DE10232113A1
(de)
|
2002-07-16 |
2004-01-29 |
Bayer Ag |
Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
|
AU2003257289A1
(en)
*
|
2002-07-26 |
2004-02-16 |
Kenneth W. Adams |
Pharmaceutical compositions for penis enlargement
|
WO2005068464A2
(en)
*
|
2003-12-15 |
2005-07-28 |
Cadila Healthcare Limited |
Process for preparing tadalafil and its intermediates
|
KR101292492B1
(ko)
|
2004-05-11 |
2013-08-01 |
이모셔널 브레인 비.브이. |
약제학적 제형물 및 여성 성기능 부전의 치료에서 그것의용도
|
US20060235005A1
(en)
*
|
2005-04-14 |
2006-10-19 |
Oak Labs, Corp. |
Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
|
US8506934B2
(en)
|
2005-04-29 |
2013-08-13 |
Robert I. Henkin |
Methods for detection of biological substances
|
US20070010525A1
(en)
*
|
2005-06-27 |
2007-01-11 |
Meyer Jackson |
Method and compositions for modulating neuropeptide hormone secretion
|
WO2007016361A2
(en)
|
2005-07-29 |
2007-02-08 |
Concert Pharmaceuticals Inc. |
Novel pharmaceutical compounds
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
WO2007033239A2
(en)
*
|
2005-09-13 |
2007-03-22 |
Elan Pharma International, Limited |
Nanoparticulate tadalafil formulations
|
JP2009512711A
(ja)
|
2005-10-21 |
2009-03-26 |
ブレインセルス,インコーポレイティド |
Pde阻害による神経新生の調節
|
CA2625210A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
Gaba receptor mediated modulation of neurogenesis
|
EP2218442A1
(en)
|
2005-11-09 |
2010-08-18 |
CombinatoRx, Inc. |
Methods, compositions, and kits for the treatment of ophthalmic disorders
|
EP1790343A1
(en)
|
2005-11-11 |
2007-05-30 |
Emotional Brain B.V. |
Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
WO2007124045A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Ampla Pharmaceuticals, Inc. |
Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
WO2007134136A2
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
US20080009502A1
(en)
*
|
2006-07-07 |
2008-01-10 |
Access Business Group International Llc |
Tadalafil solid composites
|
KR20090064418A
(ko)
|
2006-09-08 |
2009-06-18 |
브레인셀즈 인코퍼레이션 |
4-아실아미노피리딘 유도체 포함 조합물
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
EP1925307A1
(en)
|
2006-11-03 |
2008-05-28 |
Emotional Brain B.V. |
Use of 3-alpha-androstanediol in the treatment of sexual dysfunction
|
US8293489B2
(en)
|
2007-01-31 |
2012-10-23 |
Henkin Robert I |
Methods for detection of biological substances
|
EP2120570B1
(en)
|
2007-02-12 |
2012-05-16 |
DMI Biosciences, Inc. |
Treatment of comorbid premature ejaculation and erectile dysfunction
|
NZ579170A
(en)
|
2007-02-12 |
2012-05-25 |
Dmi Biosciences Inc |
Reducing side effects of tramadol
|
CA2685184A1
(en)
*
|
2007-04-25 |
2008-11-06 |
Teva Pharmaceutical Industries Ltd. |
Solid dosage forms
|
DE102007028869A1
(de)
|
2007-06-22 |
2008-12-24 |
Ratiopharm Gmbh |
Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
|
WO2009091777A1
(en)
*
|
2008-01-15 |
2009-07-23 |
Forest Laboratories Holdings Limited |
Nebivolol in the treatment of sexual dysfunction
|
EA201591353A1
(ru)
|
2008-05-02 |
2016-01-29 |
Джилид Сайэнс, Инк. |
Применение частиц твердого носителя для улучшения технологических характеристик фармацевтического агента
|
US8580801B2
(en)
|
2008-07-23 |
2013-11-12 |
Robert I. Henkin |
Phosphodiesterase inhibitor treatment
|
AR073522A1
(es)
|
2008-09-30 |
2010-11-10 |
Biolab Sanus Farmaceutica Ltda |
Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
EP2400848A4
(en)
|
2009-02-26 |
2012-07-25 |
Thar Pharmaceuticals Inc |
CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
|
DE102009033396A1
(de)
|
2009-07-16 |
2011-01-20 |
Ratiopharm Gmbh |
Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
*
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
UY33535A
(es)
*
|
2010-08-13 |
2011-12-01 |
Biolab Sanus Farmaceutuca Limitada |
Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona
|
WO2013056183A1
(en)
|
2011-10-14 |
2013-04-18 |
Array Biopharma Inc. |
Polymorphs of arry-380, a selective herb2 inhibitor and pharmaceutical compositions contianing them
|
US20150119399A1
(en)
|
2012-01-10 |
2015-04-30 |
President And Fellows Of Harvard College |
Beta-cell replication promoting compounds and methods of their use
|
MX357741B
(es)
*
|
2012-07-06 |
2018-07-23 |
Laboratorios Senosiain S A De C V Star |
Nuevas formas sólidas de inhibidores de fosfodiesterasa tipo 5.
|
WO2014055801A1
(en)
|
2012-10-05 |
2014-04-10 |
Henkin Robert I |
Phosphodiesterase inhibitors for treating taste and smell disorders
|
EP3054951A4
(en)
*
|
2013-10-07 |
2017-05-10 |
Millennium Pharmaceuticals, Inc. |
Inhibitor of breast cancer resistance protein (bcrp)
|
WO2015126944A1
(en)
|
2014-02-18 |
2015-08-27 |
Henkin Robert I |
Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell
|
WO2015200177A1
(en)
|
2014-06-23 |
2015-12-30 |
Celgene Corporation |
Apremilast for the treatment of a liver disease or a liver function abnormality
|
CN104086546B
(zh)
*
|
2014-07-14 |
2016-08-17 |
福建广生堂药业股份有限公司 |
他达拉非的药用酸盐及其制备方法
|
RU2019121646A
(ru)
|
2016-12-14 |
2021-01-15 |
Респира Терапьютикс, Инк. |
Способы и композиции для лечения легочной гипертензии и других заболеваний легких
|
EP3510997B1
(en)
|
2018-01-10 |
2020-08-05 |
Gap S.A. |
Soft gelatin capsules comprising a suspension of tadalafil
|
WO2019241585A1
(en)
|
2018-06-14 |
2019-12-19 |
Astrazeneca Uk Limited |
Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
|
WO2021245192A1
(en)
|
2020-06-04 |
2021-12-09 |
Topadur Pharma Ag |
Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
|